{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:03:04Z","timestamp":1791428584538,"version":"4.3.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00472-6","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:58:32Z","timestamp":1787903912000},"page":"365-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Polyneuropathy Assessment and Treatment Patterns in Patients with Hereditary Transthyretin Amyloidosis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3321-7064","authenticated-orcid":false,"given":"Nicholas","family":"Streicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermela","family":"Wubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"6","key":"472_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583\u201396. https:\/\/doi.org\/10.1056\/NEJMra023144.","journal-title":"N Engl J Med"},{"issue":"22","key":"472_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"472_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","volume":"19","author":"JN Buxbaum","year":"2017","unstructured":"Buxbaum JN, Ruberg FL. Transthyretin V122I cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy. Genet Med. 2017;19(7):733\u201342. https:\/\/doi.org\/10.1038\/gim.2016.200.","journal-title":"Genet Med"},{"issue":"3","key":"472_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","volume":"22","author":"DR Jacobson","year":"2015","unstructured":"Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14,333 African-Americans. Amyloid. 2015;22(3):171\u20134. https:\/\/doi.org\/10.3109\/13506129.2015.1051219.","journal-title":"Amyloid"},{"issue":"1","key":"472_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91113-6","volume":"11","author":"MM Parker","year":"2021","unstructured":"Parker MM, Damrauer SM, Tcheandjieu C, et al. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry. Sci Rep. 2021;11(1):11645. https:\/\/doi.org\/10.1038\/s41598-021-91113-6.","journal-title":"Sci Rep"},{"issue":"19","key":"472_CR6","doi-asserted-by":"publisher","first-page":"e2036","DOI":"10.1212\/WNL.0000000000207158","volume":"100","author":"S Zampino","year":"2023","unstructured":"Zampino S, Sheikh FH, Vaishnav J, et al. Phenotypes associated with the Val122Ile, Leu58His, and late-onset Val30Met variants in patients with hereditary transthyretin amyloidosis. Neurology. 2023;100(19):e2036\u201344. https:\/\/doi.org\/10.1212\/WNL.0000000000207158.","journal-title":"Neurology"},{"issue":"2","key":"472_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/mus.28414","volume":"72","author":"U Desai","year":"2025","unstructured":"Desai U, Ilieva HS, Eyer JE, Peltier AC. Peripheral nervous system involvement of hereditary transthyretin amyloidosis in the United States: a multi-center perspective. Muscle Nerve. 2025;72(2):286\u201393. https:\/\/doi.org\/10.1002\/mus.28414.","journal-title":"Muscle Nerve"},{"issue":"5","key":"472_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000200304","volume":"11","author":"VJW Zhang","year":"2025","unstructured":"Zhang VJW, O\u2019Donnell LF, Skorupinska M, et al. Peripheral neuropathy in p.Val142Ile (Val122Ile) variant hereditary transthyretin-mediated amyloidosis: United Kingdom experience. Neurol Genet. 2025;11(5):e200304. https:\/\/doi.org\/10.1212\/NXG.0000000000200304.","journal-title":"Neurol Genet"},{"key":"472_CR9","doi-asserted-by":"publisher","unstructured":"Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u2013172. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.596.","DOI":"10.1016\/j.jacc.2016.03.596"},{"issue":"6","key":"472_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/ana.24519","volume":"78","author":"LL Mariani","year":"2015","unstructured":"Mariani LL, Lozeron P, Th\u00e9audin M, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol. 2015;78(6):901\u201316. https:\/\/doi.org\/10.1002\/ana.24519.","journal-title":"Ann Neurol"},{"issue":"4","key":"472_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JND-210656","volume":"8","author":"Z Chen","year":"2021","unstructured":"Chen Z, Koh JS, Saini M, et al. Hereditary transthyretin amyloidosis: clinical and genetic characteristics of a multiracial South-East Asian cohort in Singapore. J Neuromuscul Dis. 2021;8(4):723\u201333. https:\/\/doi.org\/10.3233\/JND-210656.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"472_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-04006-6","volume":"20","author":"T Nomura","year":"2025","unstructured":"Nomura T, Misumi Y, Tasaki M, et al. Genetic and clinical features of hereditary transthyretin amyloidosis: a decade of experience at a Japanese referral center. Orphanet J Rare Dis. 2025;20(1):474. https:\/\/doi.org\/10.1186\/s13023-025-04006-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"472_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jns.70097","volume":"31","author":"G Maximiano-Alves","year":"2026","unstructured":"Maximiano-Alves G, Lavigne-Moreira C, Sim\u00f5es MV, et al. Genetic and clinical spectrum of hereditary transthyretin amyloidosis in Brazil. J Peripher Nerv Syst. 2026;31(1):e70097. https:\/\/doi.org\/10.1111\/jns.70097.","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"472_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"3","key":"472_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","volume":"23","author":"M Waddington Cruz","year":"2016","unstructured":"Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178\u201383. https:\/\/doi.org\/10.1080\/13506129.2016.1207163.","journal-title":"Amyloid"},{"issue":"2","key":"472_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40119-024-00362-9","volume":"13","author":"N Streicher","year":"2024","unstructured":"Streicher N, Amass L, Wang R, et al. Real-world effectiveness of high-dose tafamidis on neurologic disease progression in mixed-phenotype variant transthyretin amyloid cardiomyopathy. Cardiol Ther. 2024;13(2):359\u201368. https:\/\/doi.org\/10.1007\/s40119-024-00362-9.","journal-title":"Cardiol Ther"},{"issue":"1","key":"472_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153.","journal-title":"N Engl J Med"},{"issue":"1","key":"472_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):18\u201326. https:\/\/doi.org\/10.1080\/13506129.2022.2091985.","journal-title":"Amyloid"},{"issue":"15","key":"472_CR19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W Jr, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448\u201358. https:\/\/doi.org\/10.1001\/jama.2023.18688.","journal-title":"JAMA"},{"key":"472_CR20","doi-asserted-by":"publisher","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. HELIOS-B Trial Investigators. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","DOI":"10.1056\/NEJMoa2409134"},{"issue":"6","key":"472_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70627","volume":"33","author":"GS Duarte","year":"2026","unstructured":"Duarte GS, Machado TLGN, Rodrigues FB, Concei\u00e7\u00e3o I, Pareyson D, Costa JNMPG. Pharmacological interventions for hereditary transthyretin-related amyloidosis with polyneuropathy: systematic review and network meta-analysis. Eur J Neurol. 2026;33(6):e70627. https:\/\/doi.org\/10.1111\/ene.70627.","journal-title":"Eur J Neurol"},{"issue":"4","key":"472_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ana.25433","volume":"85","author":"CC Chao","year":"2019","unstructured":"Chao CC, Hsueh HW, Kan HW, et al. Skin nerve pathology: biomarkers of premanifest and manifest amyloid neuropathy. Ann Neurol. 2019;85(4):560\u201373. https:\/\/doi.org\/10.1002\/ana.25433.","journal-title":"Ann Neurol"},{"key":"472_CR23","doi-asserted-by":"publisher","first-page":"e103543","DOI":"10.2196\/103543","volume":"14","author":"G Holly","year":"2026","unstructured":"Holly G, Bean B, Beshay H, Edwards G, Streicher N. Diagnostic code ambiguity and misclassification of adults with spinal muscular atrophy: a single-center chart review. JMIR Med Inform. 2026;14:e103543. https:\/\/doi.org\/10.2196\/103543.","journal-title":"JMIR Med Inform"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00472-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00472-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00472-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:24:08Z","timestamp":1788405848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00472-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00472-6","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"3 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nicholas Streicher has received research funding from Alnylam Pharmaceuticals and has served as an internal speaker for AstraZeneca. Hermela Wubet reports no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved as exempt by the MedStar Health Research Institute Institutional Review Board (IRB ID STUDY00007934; initial approval August 29, 2024). As secondary research using existing medical records, the study was granted a waiver of informed consent and a waiver of HIPAA authorization for the use of identifiable health information, and no identifiable patient information is reported. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}